Homepage - OrbiMed

Providing tailored financing solutions and global team resources to help build
world-class healthcare companies.

From biopharmaceuticals to medical devices, digital health, diagnostics, and healthcare services, OrbiMed is scouting the globe for innovations that will help ensure humanity lives healthier, longer, and more productive lives.

We have been investing globally for over 25 years across the healthcare industry: from early-stage private companies to large multinational corporations. Our team of over 150 distinguished scientific, medical, investment, and other professionals manages approximately $20 billion across public and private company investments worldwide.

How We Invest

Meet Our Companies Driving Healthcare Innovation

Messenger RNA targeting to create life-saving therapeutics

ADARx is developing a proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies.

Learn More

Pushing targeted oncology drug discovery to new heights

Treeline Biosciences is pursuing molecular targets in oncology that are validated but difficult to drug, leveraging its four pillars of drug discovery: mechanistic biology, medicinal chemistry, computational science, and structural biology and protein science.

Learn More

Redefining Immunology and Inflammation with Precision

Mirador Therapeutics envisions a bold new era of precision medicine for immune-mediated inflammatory and fibrotic diseases driven by speed and better development accuracy.

Learn More

Powering the Age of Immune Medicine

Adaptive is a commercial-stage biotechnology company and a proven leader in measurable residual disease (MRD) testing for lymphoid cancers. The company’s primary product is clonoSEQ®, which is trusted by patients, providers, and biopharma companies for both clinical care and research. Powered by next-generation sequencing, clonoSEQ detects and tracks cancer cells that can remain during and after treatment and that may cause disease recurrence. clonoSEQ is shaping modern lymphoid cancer care—enabling clinicians to individualize therapy, lessen treatment burden, and help patients reach their treatment goals.

Learn More

A Global Leader in Antibody and ADC Oncology Therapies

Biokin is a clinical-stage company developing innovative ADCs, bi-specific, and multi-specific antibodies for the treatment of cancers. By targeting multiple signaling pathways, Biokin is seeking to overcome the insufficient anti-tumor responses typical of existing mono-antibody therapies.

Learn More

Taking a leading approach to tackle the complexities of cancer

Avenzo Therapeutics is a clinical-stage biotechnology company focused on developing next-generation oncology therapies for patients. The company’s pipeline includes potential best-in-class small molecules and antibody-drug conjugates (ADCs).

Learn More

View All